Elicio Therapeutics (ELTX) Return on Capital Employed (2021 - 2026)
Elicio Therapeutics (ELTX) reported Return on Capital Employed of 220.46% for Q1 2026, up 5082.0% on a YoY basis from 4.25% in Q1 2025, and down 10.85% quarter-over-quarter from 198.88% in Q4 2025.
Elicio Therapeutics (ELTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Elicio Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 220.46% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 5082.0% year-over-year to 220.46%; the trailing twelve-month figure through Mar 2026 stood at 220.46% (up 5082.0% YoY), and the FY2025 full-year result was 199.44%, up 7930.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 220.46%, down from 198.88% in the prior quarter.
- The five-year high for Return on Capital Employed was 20.48% in Q3 2022, with the low at 329.83% in Q2 2024.
- Historically, Return on Capital Employed has averaged 162.13% across 5 years, with a median of 189.13% in 2025.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 24473 bps — and 2025, when it jumped 9398 bps.
- Elicio Therapeutics' Return on Capital Employed stood at 92.39% in 2022, then sank by 100 bps to 185.1% in 2023, then slipped by 12 bps to 206.73% in 2024, then gained by 4 bps to 198.88% in 2025, then dropped by 11 bps to 220.46% in 2026.
- The last three Return on Capital Employed figures came in at 220.46% (Q1 2026), 198.88% (Q4 2025), and 189.13% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - | -220.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -220.46% |
| Dec 31, 2025 | -198.88% |
| Sep 30, 2025 | -189.13% |
| Jun 30, 2025 | -235.85% |
| Mar 31, 2025 | -271.28% |
| Dec 31, 2024 | -206.73% |
| Sep 30, 2024 | -226.61% |
| Jun 30, 2024 | -329.83% |
| Mar 31, 2024 | -192.23% |
| Dec 31, 2023 | -185.10% |
| Sep 30, 2023 | -141.62% |
| Jun 30, 2023 | -85.10% |
| Mar 31, 2023 | -85.37% |
| Dec 31, 2022 | -92.39% |
| Sep 30, 2022 | -20.48% |
| Jun 30, 2022 | -32.00% |
| Mar 31, 2022 | -43.12% |
| Dec 31, 2021 | -42.76% |
| Sep 30, 2021 | -67.99% |
| Jun 30, 2021 | -56.93% |